May 14, 2024 | Amygdala Neursciences and ABMRF

ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder

Amygdala Neurosciences (a private company) announced today that the Company has closed a new round of equity financing led by ABMRF, the Alcohol Beverage Medicines Research FoundaTon to fund the Company’s INDstage acTviTes for ANS-858.

August 01, 2023 | Amygdala Press Release

Amygdala Neurosciences Awarded $2.0 million NIH Grant to Conduct IND Enabling Studies

Amygdala Neurosciences (a private company) has been awarded a $2.0 million NIH grant to support the project titled "Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder." This award is made from the National Institute on Alcohol Abuse and Alcoholism (NIAAA, an Institute of the National Institutes of Health (NIH)).

July 28, 2023 | Wall Street Journal

Enjoy Alcohol, Without the Hangover

Scientists are finding ways to help people sober up faster and feel fewer bad efects

November 18, 2019 | NBC News

NIH Experiments With Drug to Reduce Opioid Cravings

The National Institutes of Health in Bethesda, Maryland, is testing an experimental drug that could save lives in the fight against the opioid epidemic.

October 17, 2019 | Amygdala Press Release

Amygdala Neurosciences Announces Dosing of the First Patient in the NIH Funded Phase 2 Proof-Of-Concept study of ANS-6637 for the Treatment of Alcohol Use Disorder

ANS-6637 is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders including…

March 21, 2019 | NIH Press Release

NIH to Test Experimental Drug to Curb Opioid Cravings

A clinical trial of an experimental drug designed to treat cravings associated with opioid use disorder (OUD) has begun in the National Institutes of Health Clinical Center.

February 16, 2017 | Amygdala Press Release

Amygdala Neurosciences Acquires GS-6637 from Gilead